Pharma / Medical

Having started out in 1985 with a paltry investment of 240,000 INR (US$18000), TORQUE PHARMACEUTICALS has grown into a force to reckon with in the pharmaceutical industry. It has managed to grow from strength to strength and has earned a reputation for itself as a leading private limited company offering healthcare solutions for all through its quality medicines that it supplies not just nationally but also to many developing countries globally. With an annual turnover of more than 1500 million INR, TORQUE has taken a huge leap in terms of production, positioning and presence in the domestic and international arena. TORQUE, which means a force that makes things turn around a focal point, has become a pivotal pharmaceutical company with efficient clockwork like mechanism for production, quality, logistics and growth. The force behind the exemplary augmentation has been steady dedication and an enthusiastic workforce. With mutual respect, sensitivity towards their needs and empathetic work conditions, the well qualified staff and workers are motivated to achieve higher goals for personal growth and for the betterment of the company that they feel proud to be associated with. At TORQUE, the pillars upon which its strength rests are "Impeccable Quality, Commitment to Excellence, Constant Innovation, Environment Conducive to Growth and Affordable Medicines."

We are Shafranto Uganda Limited, a registered pharmaceutical importer and distributor. We have existed, with vast experience in the pharmaceutical import and distribution business. We emphasize the importation and distribution of quality pharmaceutical and surgical products from reputable and genuine manufacturers around the world Our key objective is to provide a broad range of medications and surgical products to our valued customers at the most affordable and competitive price on the market. We source our pharmaceutical products directly from pharmaceutical manufacturers and distributors in Europe, the US, Canada, South Africa and selected manufacturers in Asia which are then re-checked by NDA for quality assurance. We offer branded and generic products in all major therapeutic areas in a variety of dosage forms, from tablets, capsules, ointments, creams, liquids, injectables, surgicals and a variety of relief items. Surgicals Items We offer a wide range of disposable and sterile items, surgical and theatre instruments. Shafranto import from over 20 manufacturers including well known international medical companies. We distribute as far as Kenya, South Sudan, Congo, and Tanzania Our medicines We import and distribute quality, affordable generics medicines in key therapy areas including Respiratory, CNS, CVS, Oncology, Urology, etc. Relief items and Consumables We supply and freely deliver our trusted relief items to camps, war-zone areas and manufacturing and mining sites Medipharm Industries (E.A) Limited was founded in 1971 by Rogers Collins Seguya and Mrs. Rebecca Seguya under the name Overseas Trading Company Limited. During that time, the core business of the company was importation and retailing of human pharmaceutical drugs and medical devices. However, the desire of the founders was to go into manufacturing of pharmaceuticals. In 1978, small mixing and compounding unit was started as Plot 5, Travin House, William Street, Kampala. Within one year, and due to rapid expansion, the manufacturing unit was moved to 1.2 acres at Bweyogerere on Jinja Road, twelve (12) Kilometers from Kampala. The principal place of business and registered office is plot 65, Kakajjo road, Bweyogerere. In the year 1982, the business name was changed to Medipharm Industries (E.A) Limited. The name change was registered with registrar of companies the same year. Advanced pharmaceutical manufacturing was not realized until 1984, when building modifications were made and procurement of critical production and quality control were done. This was made possible through funding from the International Development Agency (IDA), through Uganda Commercial Bank.

Nosak Healthcare is the pharmaceutical arm of Nosak Group. Established in 2008, it is affiliated to major global players in the healthcare industry in Europe and South East Asia. It also engages in local contract manufacturing of some of its products. We are Nosak Group – a proudly Nigerian industrial conglomerate with diversified interests in the Nigerian economy. We lead the way in our fields of play, which embraces the West African sub region. The Nosak Group is made of subsidiaries that benefit from strong regional and international alliances. We are administered in the best traditions of entrepreneurship. Our distinguishing virtues are built upon a strict adherence to quality, product integrity and an exceptional commitment to customer satisfaction. We are constantly seeking opportunities to add value to the prosperity of the country, its people and all our stakeholders. Thinking locally but acting globally, we serve tomorrow’s markets, today. In 1984, in the city of Kano, a seed of entrepreneurship was sown. From a retail shop selling soft drinks and snacks, the seed grew into retail trade, ice block manufacturing, transportation, distribution, importation until finally, this seed became Nosak Group. Today, the Nosak group is a key player in the Nigerian economy, offering vital services in retail, manufacturing, logistics, finance, agriculture, real estate, international trade, petroleum and health care thanks to a deep understanding of the Nigerian market and a network of local and international alliances. As many chapters make a good storybook, our subsidiaries make up crucial chapters of the story of the Nosak group and they make it a great story to tell. It all started with Nosak Agencies Limited in 1984, the pioneer company in the group which specialized in the importation and marketing of ethanol. Today, it has grown and evolved into the investment arm of Nosak group. The second chapter of the Nosak story is a somewhat natural progression to the manufacturing of ethanol and other industrial and consumer based chemicals through Nosak Distilleries. Incorporated in 2001, today, Nosak Distilleries is the largest manufacturer of ethanol in Nigeria with a storage facility of 24 million liters and currently controls more than 65% of the domestic supply market. It owns and operates a modern distillery for ethanol production at Amuwo Odofin Industrial Layout in Lagos. With an installed capacity of 400,000 litres of ethanol per day, Nosak Distilleries Limited expects to meet 70% of the local demand for ethanol and other industrial chemicals in Nigeria. To further capture the market for industrial chemicals, Zex Standard Chemicals Limited was established to import and trade chemicals like ethanol and other pharmaceutical raw materials. With facilities around Lagos, Zex Standard Chemicals is positioned to be the foremost provider of pharmaceutical chemicals in the country.

Pharmaceutical Technology is the only online platform focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals -  from senior executives to manufacturing managers and heads of procurement - require to stay on top of their field. Our international scope allows us to examine all pharmaceutical markets closely, from biotechnology to therapeutics, vaccines and more. When you combine this with one of the most comprehensive and detailed listings of pharmaceutical equipment suppliers, products and services, free white paper downloads and company press releases, you can see why Pharmaceutical Technology is the key point of reference for the pharma industry. Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format. Produced by a team of experienced editors and contributors, this monthly magazine brings together the latest insights and innovations from across the industry, including new discoveries, R&D and clinical trials, manufacturing technologies and supply chain management, as well as insiders’ views and in-depth analysis of the latest market and investment trends and regulatory changes affecting the industry.

Forrester Pharma and Lamar International are registered pharmaceutical companies focussed on providing innovative healthcare at affordable prices. We focus on successful product launches and swift generic entries, led by our vision to broaden access to quality healthcare in an affordable and efficient manner. People are the success behind any venture and Forrester Pharma and Lamar International have recruited a strong management team that has well-established relationships with the Governmental and Regulatory Authorities, Private Funders and Healthcare Professionals in South Africa. These relationships have been born from the team’s extensive industry experience which have also resulted in significant intellectual property relating to consumer and customer partnerships. The team is led by Jerome Smith, the founder of one of the first South African generic pharmaceutical companies, which he led to become one of the largest pharmaceutical companies in South Africa. Jerome is a lifelong pharmaceutical man and founder of Medpro Pharmaceutica in 1993, which later became known as Cipla Medpro. One of the first South African generic pharmaceutical companies was formed through strategically aligning his company with Cipla India. Under his leadership he led Cipla Medpro to becoming South Africa’s third largest pharmaceutical company by value. Through organic growth the company expanded from 2 employees and a humble beginning in 1993 to an organization of 720 employees in 18 years. Jerome’s vision was instrumental in introducing South Africa to Indian Pharmaceutical expertise. Jerome left Cipla Medpro in September 2012 and pursued a new venture – Forrester Pharma and Lamar International which are independent and privately owned start-up companies.